Seqirus Breaks Ground

November 16, 2018

BE&K Building Group Breaks Ground on Seqirus Manufacturing Expansion to Meet Growing Global Influenza Vaccine Demand

BE&K Building Group has been selected by Seqirus, a wholly owned subsidiary of CSL Limited, to provide construction management services for a major expansion at its manufacturing facility in Holly Springs, North Carolina.

The official ground breaking for the project was held on November 16, 2018. The event was attended by CSL CEO and Managing Director Paul Perreault, Seqirus CEO Gordon Naylor, U.S. Senator Richard Burr of North Carolina, Holly Springs Mayor Dick Sears, as well as Seqirus site leadership, BE&K Building Group leadership, project team members, and members of the community.

Seqirus is the largest cell-based influenza vaccine producer in the world. The expansion will allow Seqirus to increase capacity for formulation, fill, and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.

“According to the CDC, the 2017-2018 influenza season in the U.S. was one of the worst in recent years and influenza continues to be a public health threat,” said Seqirus President Gordon Naylor. “We are deeply committed to developing innovative solutions, including cell-based vaccines, to help reduce deaths and severe illness caused by influenza. In just three years, we have quadrupled our supply of our cell-based influenza vaccine and this major investment will enable us to meet further demand.”

Construction of the new facility is expected to be complete by 2020.

Seqirus operates state-of-the-art production facilities in the U.S., the UK, and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. Seqirus is part of CSL Limited, headquartered in Melbourne, Australia.

BE&K Building Group is concurrently providing construction management services for CSL on its campus in Kankakee, Illinois. CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza.